

Dirk J Van Veldhuisen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7952635/dirk-j-van-veldhuisen-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

306
papers

14,835
citations

61
h-index

114
g-index

348
ext. papers

19,680
ext. citations

8.2
avg, IF

6.42
L-index

#	Paper	IF	Citations
306	Relative fat mass, a new index of adiposity, is strongly associated with incident heart failure: data from PREVENT. <i>Scientific Reports</i> , 2022 , 12, 147	4.9	0
305	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. <i>Lancet, The</i> , 2022 ,	4.0	12
304	Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2022 ,	9.5	10
303	Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?. <i>Journal of Internal Medicine</i> , 2022 ,	10.8	3
302	The value of echocardiographic measurement of epicardial adipose tissue in heart failure patients. <i>ESC Heart Failure</i> , 2022 ,	3.7	2
301	Renal Compression in Heart Failure: The Renal Tamponade Hypothesis. <i>JACC: Heart Failure</i> , 2022 , 10, 175-183	7.9	3
300	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022 , 17, 228-239	6.9	0
299	Dose-limiting, adverse event-associated bradycardia with β -blocker treatment of atrial fibrillation in the GENETIC-AF trial. <i>Heart Rhythm O2</i> , 2022 , 3, 40-49	1.5	
298	Pathophysiological pathways related to high plasma GDF-15 concentrations in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	1
297	Rationale and Design of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after ST-segment Elevation Myocardial Infarction (GIPS-IV) trial. <i>American Heart Journal</i> , 2022 , 243, 167-176	4.9	2
296	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. <i>Circulation</i> , 2022 ,	16.7	7
295	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	0
294	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. <i>Cardiovascular Research</i> , 2021 , 117, 2228-2236	9.9	3
293	Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 953-963	3.9	2
292	Natriuresis guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based Treatment algorithm in Acute Heart Failure (PUSH-AHF) trial. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	5
291	Diabetes and prediabetes in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	3
290	A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021 ,	7.9	14

289	Cardiovascular Determinants of Impaired Placental Function in Women with Cardiac Dysfunction.. <i>American Heart Journal</i> , 2021 , 245, 126-126	4.9	0
288	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e021494	6.4	0
287	Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2021 , 24, 192	12.3	2
286	Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial. <i>Europace</i> , 2021 ,	3.9	1
285	Six-minute walk test: prognostic value and effects of nebivolol versus placebo in elderly patients with heart failure from the SENIORS trial. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1193-1201	6.1	1
284	Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 648-656	12.3	5
283	Impact of Geographic Region on the COMMANDER-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 201-211	7.9	4
282	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1554-1563	6.1	4
281	Epicardial fat in heart failure with reduced versus preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 835-838	12.3	9
280	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 947-953	12.3	4
279	The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 , 12, 555-567	10.3	3
278	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 983-991	12.3	16
277	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , 2021 , 23, 567-577	12.3	3
276	The bidirectional interaction between atrial fibrillation and heart failure: consequences for the management of both diseases. <i>Europace</i> , 2021 , 23, ii40-ii45	3.9	4
275	Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 1122-1130	12.3	3
274	Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study. <i>Europace</i> , 2021 , 23, 1359-1368	3.9	5
273	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1961-1973	15.1	7
272	Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e007901	7.6	2

271	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. <i>Clinical Cardiology</i> , 2021 , 44, 780-788	3.3	1
270	Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study). <i>European Journal of Heart Failure</i> , 2021 , 23, 1182-1190	12.3	5
269	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021 , 8, 3168-3179	3.7	5
268	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1308-1320	6.1	1
267	Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure. <i>American Journal of Cardiology</i> , 2021 , 147, 70-79	3	1
266	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e008075	7.6	2
265	Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction. <i>ESC Heart Failure</i> , 2021 , 8, 2458-2466	3.7	4
264	Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2021 , 23, 1170-1181	12.3	5
263	Importance of epicardial adipose tissue localization using cardiac magnetic resonance imaging in patients with heart failure with mid-range and preserved ejection fraction. <i>Clinical Cardiology</i> , 2021 , 44, 987-993	3.3	7
262	The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise. <i>Pflugers Archiv European Journal of Physiology</i> , 2021 , 473, 1301-1313	4.6	3
261	New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	2
260	The clinical and prognostic value of late Gadolinium enhancement imaging in heart failure with mid-range and preserved ejection fraction. <i>Heart and Vessels</i> , 2021 , 1	2.1	1
259	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 , 27, 808-811	3.3	0
258	Heart failure treatment up-titration and outcome and age: an analysis of BIostat-CHF. <i>European Journal of Heart Failure</i> , 2021 , 23, 436-444	12.3	6
257	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 68-78	12.3	19
256	Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 , 27, 533-541	3.3	3
255	Is acute heart failure a distinctive disorder? An analysis from BIostat-CHF. <i>European Journal of Heart Failure</i> , 2021 , 23, 43-57	12.3	5
254	Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients. <i>Surgery for Obesity and Related Diseases</i> , 2021 , 17, 64-71	3	1

253	Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. <i>Circulation: Heart Failure</i> , 2021 , 14, e007684	7.6	31
252	Relationship between body mass index, cardiovascular biomarkers and incident heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 396-402	12.3	6
251	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 776-784	12.3	3
250	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. <i>European Journal of Heart Failure</i> , 2021 , 23, 1677-1686	12.3	7
249	Impact of mitral regurgitation in patients with worsening heart failure: insights from BIostat-CHF. <i>European Journal of Heart Failure</i> , 2021 , 23, 1750-1758	12.3	8
248	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2
247	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 627-635	7.9	1
246	Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1421-1432	15.1	5
245	Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction.. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121009238	7.6	6
244	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. <i>European Heart Journal</i> , 2020 , 41, 1810-1817	9.5	277
243	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020 , 41, 2109-2117	9.5	42
242	High-Sensitivity Troponin-T and Cardiovascular Outcomes in the Community: Differences Between Women and Men. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 1158-1168	6.4	7
241	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF. <i>JACC: Heart Failure</i> , 2020 , 8, 359-368	7.9	7
240	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 953-963	3.7	3
239	Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 667-676	7.9	12
238	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIostat-CHF and ASIAN-HF registries. <i>European Journal of Heart Failure</i> , 2020 , 22, 1472-1482	12.3	14
237	What should the C (ongestive heart failure) represent in the CHA DS -VASc score?. <i>European Journal of Heart Failure</i> , 2020 , 22, 1294-1297	12.3	2
236	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020 , 8, 234-242	7.9	12

235	Clinical importance of urinary sodium excretion in acute heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 1438-1447	12.3	27
234	Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3. <i>American Heart Journal</i> , 2020 , 226, 235-239	4.9	4
233	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , 2020 , 109, 967-977	6.1	3
232	Trajectory of self-care behaviour in patients with heart failure: the impact on clinical outcomes and influencing factors. <i>European Journal of Cardiovascular Nursing</i> , 2020 , 19, 421-432	3.3	7
231	Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 903-906	12.3	0
230	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 821-833	12.3	11
229	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?. <i>Cardiac Failure Review</i> , 2020 , 6, e21	4.2	1
228	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1048-1059	6.1	12
227	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020 , 22, 70-80	12.3	14
226	Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. <i>European Journal of Internal Medicine</i> , 2020 , 71, 62-69	3.9	6
225	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020 , 22, 1147-1155	12.3	22
224	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 519-527	12.3	3
223	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1402-1411	12.3	10
222	Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study. <i>European Journal of Heart Failure</i> , 2020 , 22, 251-263	12.3	12
221	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Circulation</i> , 2020 , 141, 338-351	16.7	122
220	Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. <i>European Journal of Heart Failure</i> , 2020 , 22, 683-691	12.3	19
219	Doppler gradients, valve area and ventricular function in pregnant women with aortic or pulmonary valve disease: Left versus right. <i>International Journal of Cardiology</i> , 2020 , 306, 152-157	3.2	3
218	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. <i>Journal of Hypertension</i> , 2020 , 38, 420-425	1.9	5

217	Selenium and outcome in heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 1415-1423	12.3	38
216	Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study. <i>Europace</i> , 2020 , 22, 1619-1627	3.9	7
215	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2020 , 22, 81-89	12.3	10
214	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. <i>European Journal of Heart Failure</i> , 2020 , 22, 2102-2111	12.3	9
213	Safety and Tolerability of Sodium Thiosulfate in Patients with an Acute Coronary Syndrome Undergoing Coronary Angiography: A Dose-Escalation Safety Pilot Study (SAFE-ACS). <i>Journal of Interventional Cardiology</i> , 2020 , 2020, 6014915	1.8	6
212	Reduced right ventricular function on cardiovascular magnetic resonance imaging is associated with uteroplacental impairment in tetralogy of Fallot. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2020 , 22, 52	6.9	3
211	Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the VIP-HF study. <i>European Journal of Heart Failure</i> , 2020 , 22, 1923-1929	12.3	12
210	New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease. <i>European Heart Journal</i> , 2020 , 41, 4047-4049	9.5	3
209	Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 2093-2101	12.3	15
208	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020 , 41, 3787-3797	9.5	35
207	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020 , 142, 1236-1245	16.7	32
206	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020 , 109, 331-338	6.1	17
205	Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study. <i>Europace</i> , 2019 , 21, 563-571	3.9	14
204	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , 2019 , 394, 1254-1263	4.0	83
203	Effect of Systolic Blood Pressure on Left Ventricular Structure and Function: A Mendelian Randomization Study. <i>Hypertension</i> , 2019 , 74, 826-832	8.5	10
202	Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. <i>European Heart Journal</i> , 2019 , 40, 3616-3625	9.5	31
201	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <i>European Heart Journal</i> , 2019 , 40, 3593-3602	9.5	38
200	Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS). <i>Journal of Cardiac Failure</i> , 2019 , 25, 654-665	3.3	14

199	Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIostat-CHF Studies. <i>JAMA Cardiology</i> , 2019 , 4, 696-701	16.2	14
198	The clinical significance of interleukin-6 in heart failure: results from the BIostat-CHF study. <i>European Journal of Heart Failure</i> , 2019 , 21, 965-973	12.3	81
197	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. <i>Circulation: Heart Failure</i> , 2019 , 12, e005544	7.6	13
196	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. <i>JAMA Cardiology</i> , 2019 , 4, 515-523	16.2	34
195	Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. <i>European Journal of Heart Failure</i> , 2019 , 21, 862-873	12.3	127
194	Agreement of 2D transthoracic echocardiography with cardiovascular magnetic resonance imaging after ST-elevation myocardial infarction. <i>European Journal of Radiology</i> , 2019 , 114, 6-13	4.7	2
193	Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 732-743	12.3	37
192	Pregnancy in women with pre-existent ischaemic heart disease: a systematic review with individualised patient data. <i>Heart</i> , 2019 , 105, 873-880	5.1	15
191	Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. <i>European Heart Journal</i> , 2019 , 40, 1287-1293	9.5	27
190	T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2019 , 108, 133-141	6.1	4
189	Cancer and heart disease: associations and relations. <i>European Journal of Heart Failure</i> , 2019 , 21, 1515-1525	5.5	53
188	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 862-874	7.9	40
187	Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 586-598	7.9	13
186	Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. <i>JACC: Heart Failure</i> , 2019 , 7, 970-979	7.9	13
185	The year in cardiology 2018: heart failure. <i>European Heart Journal</i> , 2019 , 40, 651-661	9.5	19
184	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 345-351	12.3	28
183	Patients with heart failure with and without a history of stroke in the Netherlands: a secondary analysis of psychosocial, behavioural and clinical outcomes up to three years from the COACH trial. <i>BMJ Open</i> , 2019 , 9, e025525	3	1
182	Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2893-2904	15.1	17

181	B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 1553-1560	12.3	9
180	Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019 , 21, 218-226	12.3	13
179	Discussion forum response to Canepa et al. <i>European Heart Journal</i> , 2019 , 40, 705-706	9.5	1
178	Rapid right-sided deterioration in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2019 , 40, 699-702	9.5	2
177	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2019 , 108, 797-805	6.1	7
176	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2019 , 21, 877-886	12.3	34
175	Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. <i>Clinical Research in Cardiology</i> , 2019 , 108, 612-621	6.1	31
174	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019 , 21, 112-120	12.3	24
173	Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. <i>Clinical Research in Cardiology</i> , 2019 , 108, 477-486	6.1	39
172	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2019 , 20, 92-100	4.1	29
171	Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. <i>European Journal of Heart Failure</i> , 2018 , 20, 910-919	12.3	116
170	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 853-872	12.3	264
169	Causal Pathways from Blood Pressure to Larger Qrs Amplitudes a Mendelian Randomization Study. <i>Scientific Reports</i> , 2018 , 8, 5817	4.9	0
168	Heart Failure Stimulates Tumor Growth by Circulating Factors. <i>Circulation</i> , 2018 , 138, 678-691	16.7	117
167	Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. <i>European Heart Journal</i> , 2018 , 39, 2987-2996	9.5	124
166	Hyporesponsiveness to Darbeoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbeoetin Alfa in Heart Failure): Clinical and Prognostic Associations. <i>Circulation: Heart Failure</i> , 2018 , 11, e004431	7.6	7
165	N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure. <i>ESC Heart Failure</i> , 2018 , 5, 279-287	3.7	4
164	Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2018 , 11, e004519	7.6	72

163	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 386-398	15.1	22
162	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 260-267	12.3	19
161	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2018 , 20, 923-930	12.3	41
160	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018 , 253, 84-90	3.2	32
159	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , 2018 , 199, 51-58	4.9	7
158	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018 , 20, 125-133	12.3	186
157	Iron deficiency and red cell indices in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 114-122	12.3	31
156	Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2018 , 19, 425-432	4.1	54
155	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 16-37	12.3	137
154	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , 2018 , 39, 26-35	9.5	245
153	Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. <i>American Journal of Cardiology</i> , 2018 , 121, 107-112	3	16
152	Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 1559-1566	12.3	92
151	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004962	7.6	70
150	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. <i>Circulation: Heart Failure</i> , 2018 , 11, e004926	7.6	13
149	Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. <i>Thrombosis Research</i> , 2018 , 169, 123-127	8.2	37
148	OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. <i>Cardiovascular Research</i> , 2018 , 114, 1871-1882	9.9	22
147	Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. <i>ESC Heart Failure</i> , 2018 , 5, 1052-1059	3.7	1
146	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1081-1090	15.1	108

145	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018 , 39, 3867-3875	9.5	33
144	Heart failure with preserved ejection fraction: from mechanisms to therapies. <i>European Heart Journal</i> , 2018 , 39, 2780-2792	9.5	155
143	Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018 , 121, 621-627	3	7
142	Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2018 , 24, 177-185	3.3	36
141	Anemia in Heart Failure: Still Relevant?. <i>JACC: Heart Failure</i> , 2018 , 6, 201-208	7.9	43
140	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , 2018 , 104, 606-613	5.1	9
139	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018 , 15, 35	5	5
138	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018 , 271, 132-139	3.2	74
137	Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population. <i>European Journal of Heart Failure</i> , 2018 , 20, 1205-1214	12.3	38
136	Biological versus mechanical heart valve prosthesis during pregnancy in women with congenital heart disease. <i>International Journal of Cardiology</i> , 2018 , 268, 106-112	3.2	7
135	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 1269-1277	12.3	56
134	Effect of Metformin on Metabolites and Relation With Myocardial Infarct Size and Left Ventricular Ejection Fraction After Myocardial Infarction. <i>Circulation: Cardiovascular Genetics</i> , 2017 , 10,		10
133	Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 878-884	2.2	70
132	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	9
131	The importance of myocardial contractile reserve in predicting response to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017 , 19, 862-869	12.3	15
130	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , 2017 , 103, 407-413	5.1	42
129	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017 , 19, 627-634	12.3	110
128	Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017 , 19, 728-738	12.3	24

127	Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). <i>Cardiovascular Pathology</i> , 2017 , 29, 19-22	3.8	0
126	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017 , 243, 360-366	3.2	24
125	Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2885-2896	15.1	132
124	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017 , 5, 507-517	7.9	49
123	Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm-A CIBIS II analysis. <i>Clinical Cardiology</i> , 2017 , 40, 740-745	3.3	9
122	New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 645-655	4	6
121	Predictors of left ventricular remodeling after ST-elevation myocardial infarction. <i>International Journal of Cardiovascular Imaging</i> , 2017 , 33, 1415-1423	2.5	12
120	Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. <i>Clinical Research in Cardiology</i> , 2017 , 106, 598-609	6.1	43
119	The contemporary value of peak creatine kinase-MB after ST-segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality. <i>Clinical Cardiology</i> , 2017 , 40, 322-328	3.3	14
118	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume. <i>JACC: Heart Failure</i> , 2017 , 5, 92-98	7.9	86
117	Pregnancy in women with corrected aortic coarctation: Uteroplacental Doppler flow and pregnancy outcome. <i>International Journal of Cardiology</i> , 2017 , 249, 145-150	3.2	13
116	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. <i>European Journal of Heart Failure</i> , 2017 , 19, 1651-1660	12.3	59
115	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1690-1697	12.3	19
114	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIostat-CHF Subanalysis. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2128-2136	15.1	24
113	High-sensitivity C-reactive protein and long term reperfusion success of primary percutaneous intervention in ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2017 , 248, 51-56	3.2	12
112	Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension. <i>Journal of Cardiac Failure</i> , 2017 , 23, 777-782	3.3	18
111	Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT. <i>Clinical Research in Cardiology</i> , 2017 , 106, 939-946	6.1	15
110	Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	24

109	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017 , 19, 1310-1320	12.3	39
108	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 471-482	7.9	176
107	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017 , 136, 1374-1383	16.7	179
106	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 281-293	3.9	6
105	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017 , 19, 792-799	12.3	28
104	Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community. <i>European Journal of Heart Failure</i> , 2017 , 19, 348-356	12.3	18
103	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017 , 23, 231-239	3.3	22
102	Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. <i>European Journal of Heart Failure</i> , 2017 , 19, 116-125	12.3	38
101	Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017 , 19, 673-681	12.3	28
100	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). <i>American Journal of Cardiology</i> , 2017 , 119, 290-296	3	28
99	Right ventricular recovery after bilateral lung transplantation for pulmonary arterial hypertension. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017 , 24, 890-897	1.8	24
98	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2017 , 19, 1284-1293	12.3	46
97	Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2016 , 105, 10-6	6.1	11
96	Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2016 , 18, 1472-1487	12.3	128
95	Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations: The AKINESIS Study. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1420-1431	15.1	57
94	52 Genetic Loci Influencing Myocardial Mass. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1435-1448	15.1	76
93	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2217-2228	15.1	157
92	Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. <i>Nature Genetics</i> , 2016 , 48, 1557-1563	36.3	91

91	Effect of age and sex on efficacy and tolerability of β -blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. <i>BMJ, The</i> , 2016 , 353, i1855	5.9	62
90	High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. <i>European Journal of Heart Failure</i> , 2016 , 18, 814-21	12.3	11
89	A systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2016 , 18, 716-26	12.3	94
88	Twenty-eight genetic loci associated with ST-T-wave amplitudes of the electrocardiogram. <i>Human Molecular Genetics</i> , 2016 , 25, 2093-2103	5.6	20
87	Chronic ischemic mitral regurgitation and papillary muscle infarction detected by late gadolinium-enhanced cardiac magnetic resonance imaging in patients with ST-segment elevation myocardial infarction. <i>Clinical Research in Cardiology</i> , 2016 , 105, 981-991	6.1	14
86	Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1527-38	4	2
85	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	25
84	Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1030-7	13.4	129
83	Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. <i>Clinica Chimica Acta</i> , 2016 , 452, 50-7	6.2	22
82	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , 2016 , 204, 164-71	3.2	25
81	Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. <i>European Heart Journal</i> , 2016 , 37, 2577-85	9.5	61
80	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2016 , 203, 564-9	3.2	29
79	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. <i>Clinical Research in Cardiology</i> , 2016 , 105, 145-53	6.1	25
78	Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. <i>PLoS ONE</i> , 2016 , 11, e0145719	3.7	9
77	The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. <i>PLoS ONE</i> , 2016 , 11, e0168340	3.7	9
76	Signature of circulating microRNAs in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016 , 18, 414-23	12.3	125
75	Optimizing clinical use of biomarkers in high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2016 , 18, 269-80	12.3	54
74	Ischaemia in heart failure with preserved ejection fraction; is it important?. <i>European Journal of Heart Failure</i> , 2016 , 18, 577-8	12.3	3

73	Cardiac adaption during pregnancy in women with congenital heart disease and healthy women. <i>Heart</i> , 2016 , 102, 1302-8	5.1	21
72	Serial galectin-3 and future cardiovascular disease in the general population. <i>Heart</i> , 2016 , 102, 1134-41	5.1	37
71	Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 149-58	15.1	176
70	Right Ventricular Function After Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the Glycometabolic Intervention as Adjunct to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction III Trial). <i>American Journal of Cardiology</i> , 2016 , 118, 338-44	3	21
69	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , 2016 , 224, 231-239	3.2	42
68	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , 2016 , 221, 1067-72	3.2	10
67	Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 1072-81	12.3	30
66	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	55
65	Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. <i>European Journal of Heart Failure</i> , 2016 , 18, 641-9	12.3	20
64	Pulmonary valve replacement: twenty-six years of experience with mechanical valvar prostheses. <i>Annals of Thoracic Surgery</i> , 2015 , 99, 905-10	2.7	23
63	Iron deficiency and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2015 , 12, 659-69	14.8	147
62	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2015 , 36, 2310-7	9.5	20
61	Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. <i>European Heart Journal</i> , 2015 , 36, 2565-73	9.5	192
60	Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following acute myocardial infarction: the COMPASS-HF trial. <i>European Heart Journal</i> , 2015 ,	12.3	56
59	Leukocyte telomere length and left ventricular function after acute ST-elevation myocardial infarction: data from the glycometabolic intervention as adjunct to primary coronary intervention in ST elevation myocardial infarction (GIPS-III) trial. <i>Clinical Research in Cardiology</i> , 2015 , 104, 812-21	6.1	6
58	Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. <i>Nature Genetics</i> , 2015 , 47, 1282-1293	36.3	223
57	Validity and Predictive Value of a Portable Two-Channel Sleep-Screening Tool in the Identification of Sleep Apnea in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2015 , 21, 848-55	3.3	14
56	Hemoglobin levels and new-onset heart failure in the community. <i>American Heart Journal</i> , 2015 , 169, 94-101.e2	4.9	12

55	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015 , 36, 657-68	9.5	591
54	Vitamin B12 and folate deficiency in chronic heart failure. <i>Heart</i> , 2015 , 101, 302-10	5.1	17
53	Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015 , 17, 1201-7	12.3	23
52	Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. <i>European Journal of Heart Failure</i> , 2015 , 17, 1271-82	12.3	45
51	Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. <i>PLoS ONE</i> , 2015 , 10, e0125215	3.7	22
50	Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). <i>American Journal of Cardiology</i> , 2015 , 115, 100-106	4.9	14
49	The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial. <i>BMJ Open Diabetes Research and Care</i> , 2015 , 3, e000090	4.5	18
48	Cardiac function and cardiac events 1-year postpartum in women with congenital heart disease. <i>American Heart Journal</i> , 2015 , 169, 298-304	4.9	26
47	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , 2014 , 35, 1284-93	9.5	205
46	Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 457-62	7.6	50
45	Thirst trajectory and factors associated with persistent thirst in patients with heart failure. <i>Journal of Cardiac Failure</i> , 2014 , 20, 689-95	3.3	18
44	Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). <i>American Journal of Cardiology</i> , 2014 , 114, 737-42	3	44
43	Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort. <i>Circulation: Heart Failure</i> , 2014 , 7, 723-31	7.6	51
42	The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1823-32	15.1	67
41	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. <i>Nature Genetics</i> , 2014 , 46, 826-36	36.3	199
40	Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. <i>American Heart Journal</i> , 2014 , 167, 853-60.e4	4.9	105
39	Effect of right ventricular outflow tract obstruction on right ventricular volumes and exercise capacity in patients with repaired tetralogy of fallot. <i>American Journal of Cardiology</i> , 2014 , 113, 719-23	3	20
38	Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. <i>International Journal of Cardiology</i> , 2014 , 174, 268-75	3.2	105

37	The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. <i>European Journal of Heart Failure</i> , 2014 , 16, 655-62	12.3	44
36	Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. <i>Heart Rhythm</i> , 2014 , 11, 1543-50	6.7	55
35	Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: a meta-analysis of individual patient data. <i>American Heart Journal</i> , 2014 , 168, 354-362.e2 ³	4.8	48
34	Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. <i>Europace</i> , 2014 , 16, 1417-25	3.9	16
33	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. <i>European Heart Journal</i> , 2014 , 35, 2165-73	9.5	117
32	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014 , 1, 52-58	3.7	31
31	Genetic determinants of P wave duration and PR segment. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 475-81		34
30	The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA). <i>BMC Medical Genetics</i> , 2014 , 15, 140	2.1	6
29	Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1526-35	27.4	116
28	Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease. <i>Heart</i> , 2014 , 100, 1373-81	5.1	135
27	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency 2014 , 1, 52		1
26	Iron deficiency in chronic heart failure: an international pooled analysis. <i>American Heart Journal</i> , 2013 , 165, 575-582.e3	4.9	355
25	Tubular damage and worsening renal function in chronic heart failure. <i>JACC: Heart Failure</i> , 2013 , 1, 417-24	7.9	73
24	The WAP four-disulfide core domain protein HE4: a novel biomarker for heart failure. <i>JACC: Heart Failure</i> , 2013 , 1, 164-9	7.9	29
23	Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. <i>JACC: Heart Failure</i> , 2013 , 1, 21-8	7.9	97
22	B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1498-506	15.1	286
21	Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. <i>European Heart Journal</i> , 2013 , 34, 1424-31	9.5	318
20	Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. <i>European Journal of Heart Failure</i> , 2013 , 15, 1311-8	12.3	66

19	Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 525-525	2.2	
18	Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. <i>Nature Reviews Cardiology</i> , 2011 , 8, 485-93	14.8	132
17	Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. <i>Circulation</i> , 2011 , 124, 1719-26	16.7	301
16	Telomere length and outcome in heart failure. <i>Annals of Medicine</i> , 2010 , 42, 36-44	1.5	30
15	The cardiopulmonary continuum systemic inflammation as a common soil of heart and lung disease. <i>International Journal of Cardiology</i> , 2010 , 145, 172-176	3.2	47
14	Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. <i>European Journal of Heart Failure</i> , 2009 , 11, 1143-51	12.3	95
13	Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 582-588	15.1	608
12	Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). <i>Journal of the American College of Cardiology</i> , 2009 , 53, 2150-8	15.1	311
11	Severity of depressive symptoms is related to hospital admission in patients with heart failure. <i>European Journal of Cardiovascular Nursing</i> , 2008 , 7, 15-16	3.3	
10	Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. <i>European Journal of Heart Failure</i> , 2007 , 9, 962-963	12.3	1
9	Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>European Heart Journal</i> , 2007 , 28, 2208-16	18.5	161
8	1370: The impact of depressive symptoms and quality of life in HF patients compared with community dwelling elderly. <i>European Journal of Cardiovascular Nursing</i> , 2007 , 6, 40-40	3.3	
7	Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. <i>European Journal of Heart Failure</i> , 2006 , 8, 539-46	12.3	72
6	Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. <i>American Heart Journal</i> , 2005 , 149, 1106-11	4.9	132
5	Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. <i>Circulation</i> , 2002 , 106, 1777-82	16.7	1170
4	Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , 2001 , 15, 139-45	3.9	6
3	Ischemia and left ventricular dysfunction: a reciprocal relation?. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32 Suppl 1, S46-51	3.1	11
2	Alterations in the prognosis of chronic heart failure: an overview of the major mortality trials. <i>Cardiovascular Drugs and Therapy</i> , 1997 , 11, 427-34	3.9	6

- 1 Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMIT). *Journal of the American College of Cardiology*, **1993**, 22, 1564-73 15.1 139